| Expression pattern: |
UP |
| Associated gene: |
SCD, AGO2 |
| Associated microRNA: |
hsa-miR-326, hsa-miR-330-5p, hsa-miR-339-3p, hsa-miR-671-5p |
| Biological function: |
promotes proliferation; promotes cell cycle progression; inhibits ferroptosis; promotes tumor growth in vivo |
| Molecular mechanism: |
Acts as a miRNA sponge (ceRNA) to upregulate SCD, thereby protecting AML cells from ferroptosis. |
| Biological pathway or process: |
ferroptosis (inhibits); proliferation (promotes); cell cycle (promotes); ceRNA regulation (promotes); lipid metabolism (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; Bioinformatics Analysis; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Back-Splice Junction PCR / divergent primers PCR; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; Western Blot; ROC Analysis; Clinical Sample Validation |
| Clinical significance: |
circZBTB46 expression was associated with the stages of AML patients and showed high sensitivity and specificity for diagnosing AML. |
| Description: |
circZBTB46 is up-regulated in AML and functions as an oncogenic circRNA that promotes AML cell proliferation and cell-cycle progression while inhibiting ferroptosis. It mainly localizes in the cytoplasm and acts as a ceRNA (notably sponging hsa-miR-671-5p) to upregulate SCD, thereby reducing lipid peroxidation and supporting tumor growth in a cell line-derived xenograft model. |
| Confidence score: |
0.8745 |